OptimizeRx Corp., a leading healthcare technology company, announced on Monday that its Chief Executive Officer and Board Member, William Febbo, will be stepping down at the end of December 2024 to explore new opportunities, concluding his nine-year tenure. Following his departure, Febbo will continue to provide advisory support to OptimizeRx until the end of March 2025. In preparation for this transition, the company's Board of Directors has engaged a search firm to identify a suitable successor. During this period, Stephen Silvestro will assume the role of interim CEO.
Stephen Silvestro has been with OptimizeRx for over six years, having led the commercial division as Chief Commercial Officer before being appointed President last year. Silvestro brings valuable experience from his previous roles, including Vice President and General Manager at Wolters Kluwer's CCH Tagetik, alongside executive positions at Prognos, Decision Resources Group, and D.M.S.
Looking ahead, OptimizeRx has reaffirmed its financial guidance for 2024, anticipating that both revenue and adjusted EBITDA will reach the higher end of their projected ranges for the year.
The material has been provided by InstaForex Company - www.instaforex.com
Stephen Silvestro has been with OptimizeRx for over six years, having led the commercial division as Chief Commercial Officer before being appointed President last year. Silvestro brings valuable experience from his previous roles, including Vice President and General Manager at Wolters Kluwer's CCH Tagetik, alongside executive positions at Prognos, Decision Resources Group, and D.M.S.
Looking ahead, OptimizeRx has reaffirmed its financial guidance for 2024, anticipating that both revenue and adjusted EBITDA will reach the higher end of their projected ranges for the year.
The material has been provided by InstaForex Company - www.instaforex.com